Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidantong
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chidantong (also known as Chidan Maitong) is a Traditional Chinese Medicine (TCM) capsule developed by Jiangsu Chia Tai Tianqing Pharmaceutical. It is indicated for the treatment of atherosclerotic thrombotic cerebral infarction and ischemic stroke during the recovery phase, particularly for patients presenting with the 'blood stasis obstructing collaterals' pattern. The formulation is designed to promote blood circulation and resolve stasis to improve neurological outcomes. It has been evaluated in a Phase 3 randomized, double-blind clinical trial in China, where its efficacy and safety were compared against ginkgo leaf capsules in patients recovering from ischemic stroke.
- Brand names
- ChidantongChidan Maitong
- Other names
- Chidan Maitong capsule
Beyond the preview
Go deeper on chidantong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidantong.